Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Janet Woodcock says user fee revenue will increase slowly, in part because some fees will not produce much revenue until the biosimilar industry expands.
You may also be interested in...
Biosimilar User Fee Collections Drop Below Estimates, But FDA Is Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.
Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.
US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017
For the first time since the biosimilar user fee program began, FDA spent more in fees than it collected, and more than it spent in appropriated funds.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
